ClinicalTrials.Veeva
Menu

Find clinical trials for Eczema in Barcelona, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Atopic Dermatitis
Dermatitis
Pruritus
Food Hypersensitivity
Hidradenitis
Hidradenitis Suppurativa
Hypersensitivity

Eczema trials near Barcelona, CT, ESP:

A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis (ADhope 2)

The main purpose of this study is to evaluate the effectiveness of 24 weeks of lebrikizumab in improving disease severity, signs, and symptoms in adu...

Enrolling
Eczema
Dermatitis, Atopic
Other: Placebo
Biological: Lebrikizumab

Phase 3

Almirall
Almirall

Barcelona, Spain and 3 other locations

The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatiti...

Active, not recruiting
Atopic Dermatitis
Drug: Topical corticosteroid
Drug: Baricitinib

Phase 3

Lilly
Lilly

Esplugues de Llobregat, Barcelona [Barcelona], Spain and 78 other locations

The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18...

Enrolling
Eczema
Atopic Dermatitis
Drug: Placebo
Drug: Lebrikizumab

Phase 3

Lilly
Lilly

Esplugues de Llobregat, Spain and 88 other locations

The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to \<18 years of age with mode...

Invitation-only
Eczema
Atopic Dermatitis
Drug: Placebo
Drug: Lebrikizumab

Phase 3

Lilly
Lilly

Esplugues de Llobregat, Barcelona [Barcelona], Spain and 95 other locations

This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or a...

Active, not recruiting
Atopic Dermatitis
Drug: Ruxolitinib Cream
Drug: Vehicle Cream

Phase 3

Incyte
Incyte

Barcelona, Spain and 96 other locations

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Phase 3

Pfizer
Pfizer

Barcelona, Spain and 540 other locations

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

Phase 3

Amgen
Amgen

Barcelona, Catalonia, Spain and 556 other locations

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

Phase 3

AbbVie
AbbVie

Barcelona, Spain and 194 other locations

Locations recently updated

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of ado...

Invitation-only
Atopic Dermatitis
Drug: Placebo
Drug: Upadacitinib

Phase 3

AbbVie
AbbVie

Barcelona, Spain and 193 other locations

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

Active, not recruiting
Moderate-to-Severe Atopic Dermatitis
Drug: Nemolizumab

Phase 3

Galderma
Galderma

Barcelona, Spain and 342 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems